Short Answer Questions (SAQs) on Uremia

SAQ 1: Definition and Pathophysiology of Uremia

1. Accumulation of uremic toxins normally excreted by the kidney:

• BUN (blood urea nitrogen) is a hallmark marker. BUN itself poses little direct toxicity at levels <100 mg/dL, but at higher levels it contributes to bleeding complications and mental status changes.
• Urea has both direct and indirect toxic effects.
• Elevated parathyroid hormone (PTH), advanced glycosylation end products (AGEs), and "middle molecules" contribute to the uremic syndrome.
• Very few uremic toxins have been definitively identified. Correlation of BUN with uremic symptoms is extremely variable due to differences in generation rates across individuals.

1. Loss of non-excretory kidney functions:

• Fluid and electrolyte homeostasis impairment
• Hormonal dysregulation: reduced excretion or decreased degradation of PTH, FGF-23, insulin, glucagon, vitamin D, sex hormones, and prolactin
• Decreased erythropoietin production → anemia
• Decreased calcitriol (active vitamin D) → secondary hyperparathyroidism

1. Progressive systemic inflammation:

• Elevated C-reactive protein (CRP) and other acute-phase reactants
• Decline in "negative" acute-phase reactants (albumin, fetuin)
• This drives the malnutrition-inflammation-atherosclerosis/calcification (MIA) syndrome - accelerating vascular disease and CKD morbidity

SAQ 2: Clinical Manifestations of Uremia (Systems-Based)

A. Fluid, Electrolyte, and Acid-Base

B. Cardiovascular

• Pericarditis (uremic pericarditis): Chest pain with respiratory accentuation, friction rub, PR-interval depression on ECG - a classic complication indicating urgent dialysis initiation
• Accelerated atherosclerosis and cardiovascular disease (most common cause of death in dialysis patients)
• Hypertension from volume overload and RAAS activation
• Cardiomyopathy (uremic)

C. Hematological

• Anemia: Normocytic, normochromic - from decreased erythropoietin production; decreased erythropoiesis
• Platelet dysfunction: Impaired platelet aggregation → bleeding tendency (e.g., prolonged bleeding time)
• Burr cells (echinocytes): Characteristic red cell morphology in uremia - multiple small, regularly-spaced spiny projections

D. Neurological

• Uremic encephalopathy: Mental status changes, confusion, stupor, coma (in severe AKI/CKD)
• Peripheral neuropathy (restless legs, sensorimotor neuropathy in chronic uremia)
• Seizures (from hyponatremia, uremia itself)

E. Gastrointestinal

• Nausea, vomiting, anorexia (early symptoms)
• Uremic fetor (breath smelling of urine/ammonia)
• GI bleeding (from platelet dysfunction and mucosal ulceration)

F. Endocrine and Metabolic

• Secondary hyperparathyroidism (from low calcitriol and phosphate retention)
• Renal osteodystrophy (osteitis fibrosa cystica from PTH excess; osteomalacia from low vitamin D)
• Glucose intolerance (insulin resistance and impaired insulin degradation)
• Hypertriglyceridemia, dyslipidemia
• Malnutrition and protein catabolism

G. Dermatological

• Uremic pruritus (from calcium-phosphate skin deposits, secondary hyperparathyroidism)
• Uremic frost (urea crystal deposits on skin - rare, only in severe untreated uremia)
• Sallow yellow-brown discoloration

SAQ 3: Uremic Toxins

1. Small water-soluble molecules (<500 Da)

• Urea (most used marker, not the primary toxin)
• Creatinine, uric acid, guanidines, oxalate, hippurate
• These are well-cleared by conventional hemodialysis

1. Middle molecules (500-15,000 Da)

• Beta-2 microglobulin (causes dialysis-related amyloidosis)
• PTH (elevated; causes osteodystrophy)
• Advanced glycosylation end products (AGEs)
• FGF-23 (contributes to cardiovascular risk)

1. Protein-bound toxins

• Indoxyl sulfate, p-cresyl sulfate (gut-derived, vascular toxicity)
• Poorly cleared by hemodialysis

• The correlation between filtration markers (BUN, creatinine) and uremic symptoms is extremely variable
• Few uremic toxins have been definitively identified
• Accumulation of PTH, AGEs, and middle molecules contributes significantly to the full uremic syndrome

SAQ 4: Uremia in AKI vs. CKD

SAQ 5: Management of Uremia

1. Fluid and Electrolyte Management

• Salt restriction as first-line for hypertension/volume overload
• Loop diuretics (furosemide, bumetanide, torsemide) for sodium management; higher doses required in CKD due to resistance
• Combination with metolazone for diuretic resistance
• Water restriction for hyponatremia
• Potassium management: Avoid high-K foods; use patiromer (GI potassium binder); avoid K-sparing diuretics; careful monitoring with RAAS inhibitors

2. Hypertension

• Target BP <130/80 mmHg in CKD with diabetes or proteinuria >1 g/24h
• ACE inhibitors / ARBs - preferred agents: reduce intraglomerular hypertension by dilating efferent arterioles; slow CKD progression
• SGLT2 inhibitors (gliflozins) - now a cornerstone; renoprotective and cardiovascular benefit, including in advanced CKD (stage 4), also assist in K homeostasis

3. Anemia

• Erythropoiesis-stimulating agents (ESAs): epoetin, darbepoetin
• Iron supplementation (oral or IV)
• Target Hb ~10-12 g/dL (avoid over-correction)

4. Bone and Mineral Disease (CKD-MBD)

• Phosphate restriction + phosphate binders (calcium carbonate, sevelamer, lanthanum)
• Active vitamin D (calcitriol or analogs) for secondary hyperparathyroidism
• Calcimimetics (cinacalcet) to suppress PTH
• Renal osteodystrophy monitoring

5. Cardiovascular Risk Reduction

• Statins (benefit mainly early CKD; less evidence in ESRD)
• Tight glycemic control in diabetics (SGLT2 inhibitors beneficial)
• Treat hyperlipidemia and smoking

6. Uremic Pericarditis

• Indication for urgent dialysis initiation
• Anti-inflammatory drugs as adjunct

7. Renal Replacement Therapy (Dialysis/Transplantation)

• Indications (AEIOU mnemonic):
• Acidosis (refractory metabolic acidosis)
• Electrolytes (refractory hyperkalemia)
• Intoxication (uremic toxins causing encephalopathy, pericarditis, bleeding)
• Overload (refractory fluid overload/pulmonary edema)
• Uremia (symptomatic: encephalopathy, pericarditis, neuropathy)
• Modalities: Hemodialysis, peritoneal dialysis, kidney transplantation
• Renal transplantation is the best long-term option for eligible patients

SAQ 6: Uremic Pericarditis

• Chest pain, classically worse on inspiration and relieved by sitting forward
• Pericardial friction rub (pathognomonic)
• ECG: PR-interval depression (classic); diffuse ST elevation in early/non-uremic pericarditis
• Can progress to pericardial effusion and cardiac tamponade

• Urgent dialysis (hemodialysis preferred)
• Anticoagulation is generally avoided (risk of hemorrhagic pericardial effusion)
• Pericardiocentesis or pericardial window for tamponade
• NSAIDs/steroids less effective than in non-uremic pericarditis

SAQ 7: Uremic Bleeding

• Uremia impairs platelet function (platelet dysfunction - defects in adhesion, aggregation, and secretion)
• Uremic toxins interfere with platelet-vessel wall interactions, particularly von Willebrand factor (vWF) - GPIb interactions
• Decreased platelet cyclooxygenase activity
• Anemia exacerbates bleeding (reduced rheological effect of RBCs on platelet margination)

• Prolonged bleeding time (despite normal platelet count)
• Mucosal bleeding (GI hemorrhage, epistaxis)
• Post-procedural bleeding
• Ecchymoses

• Dialysis (corrects platelet dysfunction)
• Desmopressin (DDAVP): Releases vWF from endothelium; quick but short-lived effect
• Cryoprecipitate: Contains vWF and fibrinogen
• Conjugated estrogens: Longer-lasting correction of bleeding time
• Red cell transfusion / EPO: Correction of anemia improves platelet-wall interaction
• Platelet transfusion: Only if thrombocytopenia is present